Wilmington PharmaTech targets larger commercial API volumes with $50m Delaware expansion
Wilmington PharmaTech is investing $50 million to expand Delaware API capacity. Read why this could reshape U.S. small-molecule supply.
OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.
Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate
MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.
Sesh Products clears PMTA filing threshold as FDA substantive review begins
Sesh Products’ 64-SKU nicotine pouch PMTA enters FDA substantive scientific review. Analysis of what this means for independent pouch brands. Read more.
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
What Celosia Therapeutics’ Phase 1b CTx1000 trial could reveal about TDP-43 targeting in ALS
Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.
Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.
Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Avalyn Pharma moves AP02 into Phase 2, exploring whether nebulized delivery can improve risk benefit balance in IPF
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.